Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 10/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5658608 | 0.92 | PPARA (0.33) | PPARGF2PPARAMTNR1AMTNR1B | |
| SCHEMBL5662525 | 0.91 | MTNR1A (0.34) | F2PPARAMTNR1AMTNR1B | |
| Arginine SCHEMBL5660445 | 0.89 | PPARG (0.47) | PPARGPPARAMTNR1AMTNR1B | |
| Arginine SCHEMBL5660450 | 0.89 | PPARG (0.47) | PPARGPPARAMTNR1AMTNR1B | |
| SCHEMBL5662393 | 0.87 | CA12 (0.36) | PPARGPPARA | |
| SCHEMBL5660731 | 0.84 | PPARA (0.33) | PPARGPPARA | |
| SCHEMBL5660965 | 0.83 | PPARA (0.32) | PPARGPPARA | |
| SCHEMBL5661026 | 0.83 | MTNR1A (0.35) | PPARGPPARAMTNR1AMTNR1B | |
| SCHEMBL5661036 | 0.81 | PPARA (0.35) | PPARGPPARAMTNR1AMTNR1B | |
| SCHEMBL5660227 | 0.80 | MCL1 (0.38) | PPARGPPARAMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-04-26 | — | — | US | disclosed |
| EP-1680397-A2 | NOVEL COMPOUNDS AND THEIR USE AS ANTIDIABETIC AND HYPOLIPIDEMIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dr. Reddy's Laboratories Ltd. (IN) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005040102-A2 | NOVEL COMPOUNDS AND THEIR USE AS ANTIDIABETIC AND HYPOLIPIDEMIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S LABORATORIES LTD. (IN) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093476-A1 | Novel compounds and their use in medicine,as antidiabetic and hypolipidemic agents, process for their preparation and pharmaceutical compositions containing them | GPR119, NR1H3, NR1H2 | PPARG 170/4885F2 3263/4885PPARA 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.